Yes, there are potential risks associated with the overuse of Tigecycline. According to the FDA drug safety communication [3], there is an increased risk of death in patients treated with Tigecycline compared to other antibiotics. This risk is primarily associated with serious infections, and the FDA has required a updated boxed warning to be included in the drug labeling to highlight this risk.

Additionally, the National Center for Biotechnology Information (NCBI) states in their antibiotics handbook [2] that Tigecycline has been associated with a higher all-cause mortality rate compared to other antibiotics, particularly in patients with ventilator-associated pneumonia, catheter-related bloodstream infections, and complicated skin and skin structure infections.

It is important to note that Tigecycline, as mentioned in the drug patent watch [1], is a broad-spectrum antibiotic, and its overuse can contribute to the development of antibiotic resistance. This can make it difficult to treat infections in the future.

In summary, the potential risks associated with Tigecycline overuse include an increased risk of death, higher all-cause mortality rate, and the potential to contribute to antibiotic resistance.

Sources:
[1] <https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE>
[2] <https://www.ncbi.nlm.nih.gov/books/NBK549905/>
[3] <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics>